Screener
Denali Therapeutics Inc. DNLI Business Segments — Personnel related research and development expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept dnli:PersonnelRelatedResearchAndDevelopmentExpense.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
| Line item | Therapeutics Segment / Three Months Ended June 30, 2026 | Therapeutics Segment / Three Months Ended June 30, 2025 | Therapeutics Segment / Six Months Ended June 30, 2026 | Therapeutics Segment / Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of goods sold | 93 | — | 93 | — |
| External research and development expenses - TV programs, including cost sharing | 40,419 | 37,594 | 78,883 | 84,052 |
| Other research and development expenses, including small molecule programs | 16,494 | 24,847 | 40,048 | 54,347 |
| Personnel related research and development expenses | 40,106 | 40,255 | 81,934 | 80,524 |
| Total research and development expenses | 97,019 | 102,696 | 200,865 | 218,923 |
| Personnel related selling, general and administrative expenses | 22,921 | 20,115 | 45,485 | 38,853 |
| Other selling, general and administrative expenses | 13,362 | 12,152 | 24,309 | 22,767 |
| Total selling, general and administrative expenses | 36,283 | 32,267 | 69,794 | 61,620 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Denali Therapeutics Inc.'s business segments — personnel related research and development expenses?
- Denali Therapeutics Inc. (DNLI) reported business segments — personnel related research and development expenses of $40.11M in Q2 2026.
- How has Denali Therapeutics Inc.'s business segments — personnel related research and development expenses changed year-over-year?
- Denali Therapeutics Inc.'s business segments — personnel related research and development expenses decreased by 0.4% year-over-year, from $40.26M to $40.11M.
- What is the long-term trend for Denali Therapeutics Inc.'s business segments — personnel related research and development expenses?
- Over 3 years (2022 to 2025), Denali Therapeutics Inc.'s business segments — personnel related research and development expenses has grown at a 5.3% compound annual growth rate (CAGR), from $144.02M to $168.22M.
- What does business segments — personnel related research and development expenses mean?
- Includes all compensation, benefits, and stock-based compensation for employees directly involved in research and development activities. This metric serves as a proxy for the company's investment in human capital and scientific talent. High levels of these expenses indicate a focus on building internal expertise to drive long-term therapeutic innovation.
Ask your AI about Denali Therapeutics Inc.'s business segments — personnel related research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude